Literature DB >> 23088941

Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis.

James D Chalmers1, Adam T Hill.   

Abstract

Bronchiectasis is a chronic inflammatory lung disease. The underlying cause is not identified in the majority of patients, but bronchiectasis is associated with a number of severe infections, immunodeficiencies and autoimmune disorders. Regardless of the underlying cause, the disease is characterised by a vicious cycle of bacterial colonisation, airway inflammation and airway structural damage. Inflammation in bronchiectasis is predominantly neutrophil driven. Neutrophils migrate to the airway under the action of pro-inflammatory cytokines such as interleukin-8, tumour necrosis factor-α and interleukin-1β, all of which are increased in the airway of patients with bronchiectasis. Bacterial infection persists in the airway despite large numbers of neutrophils that would be expected to phagocytose and kill pathogens under normal circumstances. Evidence suggests that neutrophils are disabled by multiple mechanisms including cleavage of phagocytic receptors by neutrophil elastase and inhibition of phagocytosis by neutrophil peptides. Complement activation is impaired and neutrophil elastase may cleave activated complement from pathogens preventing effective opsonisation. Organisms also evade clearance by adapting to chronic infection. The formation of biofilms, reduced motility and the down-regulation of virulence factors are among the strategies used to subvert innate immune mechanisms. Greater understanding of the mechanisms underlying chronic colonisation in bronchiectasis will assist in the development of new treatments for this important disease.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23088941     DOI: 10.1016/j.molimm.2012.09.011

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  46 in total

1.  Intravenous immunoglobulin replacement treatment reduces in vivo elastase secretion in patients with common variable immune disorders.

Authors:  Alessandro Prezzo; Filomena M Cavaliere; Cinzia Milito; Caterina Bilotta; Metello Iacobini; Isabella Quinti
Journal:  Blood Transfus       Date:  2018-07-17       Impact factor: 3.443

2.  Immunity status of invasive pulmonary aspergillosis patients with structural lung diseases in Chinese adults.

Authors:  Shuo Liang; Rong Jiang; Hai-Wen Lu; Bei Mao; Man-Hui Li; Cheng-Wei Li; Shu-Yi Gu; Jiu-Wu Bai; Jin-Fu Xu
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

3.  Virulence adaptations of Pseudomonas aeruginosa isolated from patients with non-cystic fibrosis bronchiectasis.

Authors:  Taylor E Woo; Jessica Duong; Nicole M Jervis; Harvey R Rabin; Michael D Parkins; Douglas G Storey
Journal:  Microbiology       Date:  2016-12       Impact factor: 2.777

4.  Ciliary and immune dysfunctions and their genetic background in patients with non-cystic fibrosis bronchiectasis in Central Iran.

Authors:  Shakiba Hassanzadeh; Somayeh Sadeghi; Mahbube Jafari; Somayeh Najafi; Newsha Molavi; Roya Sherkat
Journal:  Ir J Med Sci       Date:  2022-04-07       Impact factor: 1.568

5.  Prognostic Factors in Adult Patients with Non-Cystic Fibrosis Bronchiectasis.

Authors:  Betina Charvet Machado; Patrícia Santos Jacques; Louise Piva Penteado; Paulo de Tarso Roth Dalcin
Journal:  Lung       Date:  2018-09-25       Impact factor: 2.584

6.  Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency.

Authors:  Derek W Russell; Amit Gaggar; George M Solomon
Journal:  Ann Am Thorac Soc       Date:  2016-04

7.  Aberrant epithelial remodeling with impairment of cilia architecture in non-cystic fibrosis bronchiectasis.

Authors:  Zhuang-Gui Chen; Ying-Ying Li; Zhao-Ni Wang; Ming Li; Hui-Fang Lim; Yu-Qi Zhou; Liang-Ming Cai; Ya-Ting Li; Li-Fen Yang; Tian-Tuo Zhang; De-Yun Wang
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

8.  The bronchiectasis severity index. An international derivation and validation study.

Authors:  James D Chalmers; Pieter Goeminne; Stefano Aliberti; Melissa J McDonnell; Sara Lonni; John Davidson; Lucy Poppelwell; Waleed Salih; Alberto Pesci; Lieven J Dupont; Thomas C Fardon; Anthony De Soyza; Adam T Hill
Journal:  Am J Respir Crit Care Med       Date:  2014-03-01       Impact factor: 30.528

9.  Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis.

Authors:  James D Chalmers; Kelly L Moffitt; Guillermo Suarez-Cuartin; Oriol Sibila; Simon Finch; Elizabeth Furrie; Alison Dicker; Karolina Wrobel; J Stuart Elborn; Brian Walker; S Lorraine Martin; Sara E Marshall; Jeffrey T-J Huang; Thomas C Fardon
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

Review 10.  Continuous versus intermittent antibiotics for bronchiectasis.

Authors:  Tim Donovan; Lambert M Felix; James D Chalmers; Stephen J Milan; Alexander G Mathioudakis; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2018-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.